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Abstract 
 
Background: Atrial fibrillation (AF) is the most common type of arrhythmia. The definition of 
AF in patients with cardiac implantable electronic devices (CIEDs) is not clear, and the 
appropriate treatment guideline for patients with episodes of AF has not been established yet. 
Additionally, little is known about the incidence of AF and embolic stroke events in Japanese 
patients with CIEDs. The purposes of this study were to identify the incidence of embolic stroke 
events in Japanese patients with and without AF events detected by CIEDs and to examine the 
risk factors of embolic stroke events. 
Methods: I retrospectively analyzed the database of our CIED clinic. Every 6 months, episodes 
of AF were checked by CIEDs. Using univariate (Student’s t test and Fisher’s exact test) and 
multivariate analyses, I examined the characteristics and incidence of embolic stroke events and 
investigated the relationship between episodes of AF and the incidence of embolic stroke events. 
Results: In this study, I enrolled 348 consecutive patients who had no prior history of AF and 
were not administering anticoagulants (follow-up period, 65±58 months; age, 70±16 years; male 
sex, 64%; implantable cardioverter defibrillator, 55%). The mean CHADS2 and CHA2DS2-VASc 
scores were 1.7±1.1 and 2.8±1.5 points, respectively. Fifty-five patients (16%) had AF events 
detected by CIEDs that lasted for ≥30 seconds, and 23 patients (6.6%) had embolic stroke during 
the follow-up period. Multivariate analysis demonstrated that independent predictors for embolic 
stroke were a left atrial diameter ≥40 mm (odds ratio [OR] 8.2, 95% confidence interval [CI] 
0.93-72.7, p=0.021) and episodes of AF (OR 12.5, 95% CI 1.96-46.3 p=0.0043). 
Conclusions: Embolic stroke events are common in Japanese patients with CIEDs. AF events 
lasting ≥30 seconds and an enlarged left atrium are the risk factors of embolic stroke in this 
population. 
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Introduction 
Atrial fibrillation (AF) is the most common type of arrhythmia, increases with age, and presents 
with a wide spectrum of symptoms and severity. Paroxysmal, persistent, and permanent forms 
require very individualized approaches to management. AF-related embolic stroke tends to be more 
severe, and its mortality rate is higher than that of stroke without AF. The definition of AF in 
patients with cardiac implantable electronic devices (CIEDs) is not clear, and the appropriate 
treatment guideline in patients with AF episodes has not been established yet. Recent CIEDs have 
led to an improvement in the early detection of atrial arrhythmic episodes, especially in patients 
who are asymptomatic. Previous studies showed that atrial high-rate episodes (AHREs) detected by 
CIEDs are associated with embolic stroke events in the Western population. The relationship 
between AHREs and embolic stroke events has been recently described in the Japanese population 
too. However, little is known about the incidence of AF and embolic stroke events in Japanese 
patients with CIEDs who have no prior AF and take no anticoagulant. Therefore, this study was 
designed to identify the incidence of embolic stroke events in Japanese patients with CIEDs who 
had no history of AF and had not received anticoagulant therapy, and to examine the risk factors of 
embolic stroke events. 
 
 
Methods 
Study design and patient population 
I retrospectively analyzed the database of the CIED clinic of Chiba University Hospital. I enrolled 
the patients receiving pacemakers and implantable cardioverter defibrillators (ICDs) between May 
1980 and May 2016. Every 6 months, AHREs were checked by the CIEDs after implantation. 
Intracardiac electrograms captured by the CIEDs were reviewed by at least 2 experienced 
electrophysiologists, and I respectively confirmed episodes of AF detected by the CIEDs. Patients 
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who had a history of AF or had not received anticoagulant therapies were excluded. History of AF 
was defined as AF documented by 12-lead electrocardiography (ECG) or Holter ECG monitoring. 
If the pacing mode of VVI or AAI was set in patients with CIEDs, I excluded these patients. 
I examined the characteristics and incidence of embolic stroke events and investigated the 
relationship between AF episodes and the incidence of embolic stroke events. Clinical data were 
obtained from patients’ medical records and by interview with the patient when need. The 
hospital’s ethics committee approved this study. 
 
Statistical analysis 
The longer duration of an AHRE contributes to the higher risk of embolic stroke; thus, I drew a 
receiver operating characteristics (ROC) curve using this factor. I confirmed the cut-off duration 
that had the best sensitivity and specificity to predict the onset of embolic stroke. After dividing 
patients with or without AHREs based on the cut-off duration, I compared the clinical information 
including age, follow-up period, sex, complication of congestive heart failure, hypertension, 
diabetic mellitus, chronic obstructive pulmonary disease, coronary artery disease, sick sinus 
syndrome and atrioventricular block, left atrial dilatation, left ventricular ejection fraction, the 
proportion of ICDs, CHADS2 score, CHA2DS2-VASc score, and HAS-BLED score between the 2 
groups. In addition, I compared these characteristics between patients with and without embolic 
stroke events using the Student’s t test and Fisher’s exact test in univariate analysis. Multivariate 
analysis with the logistic regression analysis was performed to identify risk factors of embolic 
stroke, and the characteristics with a p-value less than 0.05 in univariate analysis were used. I 
defined the statistical threshold as p<0.05. SPSS Statistics 25.0 software (IBM Corp., Armonk, NY, 
USA) was used to perform all statistical analyses. 
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Results 
I enrolled 620 consecutive patients who were followed up at our CIED clinic. Figure 1 shows the 
flow diagram of this study. Fifty-five patients were excluded because their pacing mode was set to 
VVI or AAI, and 205 patients who had a history of AF or had received anticoagulant therapies 
were excluded. Among 360 patients, 12 patients were excluded because of lack of details on the 
device data due to terminal illness limiting survival, lead failure, or extraction. Therefore, 348 
patients were included in this study (follow-up period, 65±58 months; age, 70±16 years; male sex, 
64%; ICD, 55%). The mean CHADS2 score and CHA2DS2-VASc score were 1.7±1.1 points and 
2.8±1.5 points, respectively. 
 
Fig 1. Study flow chart.  
 
Implanted devices and detection of atrial high-rate episodes 
All patients received dual-chamber CIEDs from Medtronic, Abbott, and Biotronik based on a 
class I or IIa indication according to the Japanese Circulation Society. The devices were 
programmed to the nominal setting of each device, and AHRE was detected when the atrial rate 
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reached 175, 190, and 200 beats per minute according to the Medtronic, Abbott, and Biotronik 
devices, respectively. 
ROC curve analysis was performed, and the area under the curve (AUC) was calculated to 
determine the best duration of AHREs for predicting the risk of embolic stroke onset. ROC curve 
analysis confirmed that 30 seconds was the best cut-off time of AHREs detected by CIEDs for an 
embolic stroke event (AUC=0.67) (Fig. 2). During the follow-up (median 84 months), 75 of 348 
patients (22%) had AHREs detected by CIEDs. Of those, 55 patients (16%) had an AF episode 
lasting for ≥30 seconds, and 14 patients (4.0%) had an AHRE lasting for <30 seconds, as detected 
by CIEDs. Additionally, 6 patients (0.57%) had regular supraventricular tachycardia (including 
atrial flutter and atrial tachycardia) lasting for ≥30 seconds. 
Table 1 shows baseline characteristics of the 2 groups (patients with and without episodes of AF). 
Sick sinus syndrome was more prevalent in patients with episodes of AF episode than in those 
without episodes of AF (44% versus [vs.] 24%, p<0.0028). On the contrary, atrioventricular block 
was more prevalent in patients without episodes of AF than in those with episodes of AF (66% vs. 
20%, p<0.001). Additionally, patients with episodes of AF had significantly higher CHADS2 and 
CHA2DS2-VASc scores than those without episodes of AF (2.0±1.5 vs. 1.6±1.0, p<0.001 and 
3.3±1.9 vs. 2.7±1.4, p<0.001). 
Fig 2. Receiver-operating characteristic (ROC) 
curve for predicting embolic stroke onset. The 
area under the curve (AUC) was calculated to 
determine the best duration of atrial high-rate 
episodes (AHREs) for predicting the risk of 
embolic stroke onset. ROC curve analysis 
confirmed that 30 seconds is the best cut-off 
time of AHREs detected by cardiac implantable 
electronic devices for predicting the risk of 
embolic stroke events (AUC=0.67). 
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Table 1. Baseline characteristics of study patients 
 
All  
(N=348) 
Patients 
with AF episode 
 (N=55) 
Patients 
without AF episode 
(N=293) 
p-value 
 Age 70±16 73±14 69±15 0.19 
 Follow-up period（month） 65±58 69±42 60±36 0.29 
 Sex (male, %) 224 (64) 40 (72) 184 (62) 0.17 
 Congestive heart failure, n (%) 171 (49) 28 (51) 143 (48) 0.30 
 Hypertension, n (%) 162 (46) 22 (40) 154 (40) 1.00 
 DM, n (%) 63 (18) 13 (24) 50 (17) 0.25 
 COPD, n (%) 18 (5.2) 3 (5.4) 15 (5.1) 1.0 
 Coronary artery disease, n (%) 81 (23) 13 (24) 68 (23) 1.0 
 eGFR ≤65, n (%) 125 (36) 23 (42) 102 (34) 0.35 
 BNP (pg/ml) 70±58 82±35 68±56 0.47 
 TSH (μIU/ml) 1.7±1.0 1.4±0.8 1.8±1.2 0.38 
 FT4 (ng/ml) 1.2±0.1 1.16±0.2 1.20±0.2 0.82 
 LAD (mm) 41±6.8 42±7 41±7 0.16 
 Left ventricular ejection fraction (%) 53±17 53±18 53±17 0.98 
 ICD, n (%) 193 (55) 28 (51) 165 (56) 0.46 
 Atrial pacing rate (%) 25±31 24±30 25±32 0.79 
 Ventricular pacing rate (%) 48±47 51±46 47±48 0.45 
 Sick sinus syndrome, n (%) 97 (27) 25 (44) 72 (24) 0.0028 
 Atrioventricular block, n (%) 203 (58) 11 (20) 192 (66) <0.001 
 CHADS2 score 1.7±1.1 2.0±1.5 1.6±1.0 <0.001 
 CHA2DS2-VASc score 2.8±1.5 3.3±1.9 2.7±1.4 <0.001 
 HAS-BLED score 1.7±1.2 1.9±1.3 1.6±1.2 0.14 
DM; diabetes mellitus, COPD; chronic obstructive pulmonary disease, eGFR; estimated glomerular filtration rate,   
BNP; brain natriuretic peptide, TSH; Thyroid Stimulating Hormone, FT4; free thyroxine 4, LAD; left atrial diameter,         
ICD; implantable cardioverter defibrillator  
 
 
Table 2. Incidence of major stroke events. 
 
All  
(N=348) 
Patients  
with AF episode 
 (N=55) 
Patients  
without AF episode 
(N=293) 
p-value 
 Embolic stroke, n (%) 23 (6.6) 13 (24) 10 (3.4) <0.001 
 Cerebral bleeding, n (%) 5 (1.4) 2 (3.6) 3 (1.0) 0.18 
 
8/14 
 
Stroke events 
In this study, embolic stroke, including transient ischemic attack and cerebral bleeding, was 
diagnosed by an experienced neurologist based on the patient’s history, symptoms, and imaging 
findings. During the follow-up, 23 of 348 patients (6.6%) had embolic stroke. Thirteen patients 
(4.1%/year) and 10 patients (0.7%/year) had embolic stroke events with and without episodes of 
AF, respectively. Therefore, the incidence of embolic stroke events was 6.0 times higher in patients 
with episodes of AF than in those without episodes of AF (Table 2). Additionally, 5 of 348 patients 
(1.4%) had cerebral bleeding. Two patients (0.63%/year) and 3 patients (0.2%/year) had cerebral 
bleeding events with and without episodes of AF, respectively, and the incidence of cerebral 
bleeding events was 3.0 times higher in patients with episodes of AF than in those without episodes 
of AF (Table 2). 
 
Relationship between episodes of AF and the incidence of embolic stroke events 
The comparison of characteristics among patients with and without embolic stroke is shown in 
Table 3 (embolic stroke group vs. non-embolic group). The proportion of patients with new-onset 
AF episode and left atrial diameter were significantly higher in the embolic stroke group than in the 
non-embolic stroke group. I assessed the cut-off value of age ≥70 and left atrial diameter ≥40 mm 
using ROC curve analysis. In multivariate logistic regression analysis (Table 2), independent 
predictors for embolic stroke were new-onset AF episode (odd ratio [OR] 12.5, 95% confidence 
interval [CI] 1.96–46.3, p=0.0043) and an enlarged left atrium ≥40 mm (OR 8.2, 95% CI 0.93–
72.7, p=0.021). 
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Table 3. Risk Factors of Embolic stroke. 
(i) Univariate analysis (unpaired t test or Fisher’s exact test) 
 
Embolic stroke 
group 
 
(n=23) 
Non-embolic stroke 
group 
 
(n=325) 
p-value 
 Age ≥ 70, n (%) 14 (63) 176 (54) 0.35 
 Follow-up period (month) 88±64 67±67 0.28 
 Male, n (%) 19 (82) 205 (63) 0.33 
 Congestive heart failure, n (%) 15 (64) 156 (48) 0.37 
 Hypertension, n (%) 12 (54) 150 (49) 0.54 
 DM, n (%) 4 (18) 59 (18) 1.00 
 COPD, n (%) 2 (9) 16 (5) 0.39 
 New-onset AF episode, n (%) 13 (56) 42 (13) 0.0012 
 Coronary artery disease, n (%) 6 (26) 75 (23) 0.74 
 LAD ≥ 40mm, n (%) 15 (64) 123 (38) 0.035 
 Left ventricular ejection fraction ≤ 60%, n (%) 15 (64) 221 (68) 0.72 
 ICD, n (%) 11 (48) 182 (56) 0.22 
 Sick sinus syndrome, n (%) 9 (39) 88 (27) 0.68 
 Atrioventricular block, n (%) 8 (35) 195 (60) 0.23 
DM; diabetes mellitus, COPD; chronic obstructive pulmonary disease, AF; atrial fibrillation, LAD; left atrial diameter, 
ICD; implantable cardioverter defibrillator  
 
(ii) Multivariate analysis (logistic regression) 
 Odds Ratio 95% Confidence interval p-value 
    New-onset AF episode 12.5 1.96-46.3 0.0043 
    LAD ≥ 40mm 8.2 0.93-72.7 0.021 
AF; atrial fibrillation, LAD; left atrial diameter 
 
 
Discussion 
We are facing an increasing use of CIEDs, which have rapidly evolved from simple pacing to 
devices including several diagnostic functions. However, these functions are not adequately 
exploited in current clinical practice and several redundant diagnostic tests, like a 24-hour 
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electrocardiogram monitoring, are still prescribed to CIED patients, leading to an increase of costs 
and a delay in final diagnosis. 
The main finding of this study was that AF detected by CIEDs that lasted for ≥30 seconds was 
associated with embolic stroke events in a Japanese population that had no history of AF. In 
previous studies regarding AHREs, patients with a history of AF were also included and their 
proportions ranged from 20% of the patients in TRENDS to 100% of the patients in the Italian 
AT500 Registry. Therefore, the solo effect of AHREs on the risk of embolic stroke cannot be 
reliably evaluated based on these studies. The ASSERT study is the only large, prospective trial to 
assess the relationship between AHREs and thromboembolism in patients without a history of 
clinical AF. In the ASSERT study, an AHRE was defined as an atrial rate of at least 190 beats per 
minute lasting for at least 6 minutes. During the follow-up period, a stroke or systemic embolism 
occurred in 4.2% (1.7%/year) of patients in whom AHREs had been detected compared to 1.7% 
(0.7%/year) of patients in whom AHREs had not been detected.  
In the TRENDS trial, AHRE was defined as an atrial rate >175 beats per minute, lasting ≥5.5 
hours. In an analysis of the MOde Selection Trial, AHRE was defined as an atrial rate >220 beats 
per minute lasting ≥5 minutes. In this study, the ROC curve showed that the best cut-off duration 
time of AHREs for predicting the risk of embolic stroke was 30 seconds (Fig. 2). All cardiac 
electrograms obtained from CIEDs should be reviewed to exclude artifacts and AF should be 
reviewed by qualified clinicians to verify diagnostic accuracy. Retrospective review of device-
derived data has confirmed that most of atrial tachyarrhythmias represent paroxysmal AF. 
However, False detection may occur due to far-field R-wave oversensing by the atrial lead or runs 
of premature atrial complexes. In addition, device-stored data based solely on marker channels, 
without electrocardiograms, cannot be used to verify AF due to the potential for diagnostic errors 
caused by oversensing or undersensing by the atrial lead. Therefore, we should focus on AFs 
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detected by CIEDs that last for ≥30 seconds, not AHRE, in order to prevent patients without AF 
from developing embolic stroke. 
During the follow-up (median 84 months), 75 of 348 patients (22%) had AHREs detected by 
CIEDs in this study. Of those, 55 patients (16%) had an AF episode lasting for ≥30 seconds. Early 
detection of asymptomatic episodes of AF is important for clinical reasons. AHREs are correlated 
with a 5- to 6-fold increased risk of developing clinical AF, as evidenced in the MOde Selection 
Trial and ASSERT study. Additionally, there are several studies in the literature that show an 
updated model for embolic stroke in AF/AHRE. In this model, atrial cardiomyopathy plays a key 
role and can result in both AHRE and AF. Atrial cardiomyopathy can be characterized by atrial 
dilatation, mechanical dysfunction, fibrosis, and/or endothelial dysfunction and cause 
hypercoagulability, i.e., the increased potential of blood or plasma to generate thrombin and fibrin. 
The updated model shows that atrial cardiomyopathy can lead to embolic stroke through 
hypercoagulability and that hypercoagulability can lead to AF/AHRE through atrial 
cardiomyopathy. My data suggest that 13 patients (4.1%/year) and 10 patients (0.7%/year) had 
embolic stroke events with and without episodes of AF, respectively. Therefore, the incidence of 
embolic stroke events was 6.0 times higher in patients with episodes of AF than in those without 
episodes of AF. Episodes of AF lasting for ≥30 seconds may cause atrial cardiomyopathy and 
become the risk of embolic stroke in Japanese patients with a CIED.  
Independent predictors for embolic stroke were not only new-onset AF episode but also an 
enlarged left atrium ≥40 mm. Previous studies have shown that the duration of AF, left atrial 
appendage (LAA) emptying velocity, and left atrial diameter are significant predictors of long-term 
sinus rhythm maintenance. Some degenerative changes can develop in both the left atrium and 
LAA due to structural or electrical remodeling in patients with AF. The changes that are suggested 
may cause heterogeneous atrial conduction and slow or anisotropic conduction in atrium, and they 
are considered significant factors in the pathogenesis of AF. Furthermore, P-wave dispersion has 
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been reported to be a simple, useful electrocardiographic marker for reflecting atrial 
inhomogeneous and anisotropic conduction.  
Anticoagulation might be based on a comprehensive assessment of the risk and benefit. Regarding 
the timing of starting anticoagulant therapy in patients with AHRE without a history of AF, there is 
no guideline because of a lack of evidence in support of antithrombotic treatment. The 2016 
European Society of Cardiology guidelines indicate that it is uncertain whether AHRE (>5–6 min 
and >180 bpm) requires the same therapeutic approach as clinically overt AF, and recommend that 
patients with AHRE should have further electrocardiogram monitoring to document overt AF 
before initiating oral anticoagulation therapy. Although clinical AF such as paroxysmal or 
persistent AF documented by electrocardiogram monitoring plays a major role in the pathogenesis 
of cardioembolic stroke, covert AF including asymptomatic AF and AHRE are believed to 
contribute to the pathogenesis of embolic stroke events. However, a recent consensus document of 
the European Heart Rhythm Association regarding device-detected subclinical atrial 
tachyarrhythmias indicates that oral anticoagulation is recommended for patients with two 
additional CHA2DS2-VASc risk factors (≥2 in males or ≥3 in females) with AF burden >5.5 h/day. 
Two large-scale randomized clinical trials of anticoagulation for patients with device-detected 
AHRE are ongoing: the ARTESiA trial (Apixaban for the Reduction of Thrombo-Embolism in 
Patients With Device-Detected Sub-Clinical Atrial Fibrillation) and the NOAH trial (Non-Vitamin 
K Antagonist Oral Anticoagulants in Patients With Atrial High Rate Episodes). These results are 
eagerly awaited.  
 
Limitations 
The present study has several limitations. First, this study had a single-center, retrospective, 
observational design with a relatively small number of patients with CIEDs. Second, I collected 
clinical data at the time of CIED implantation, so the data at follow-up were not considered. Third, 
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this study did not consider the frequency of AF episodes, rhythm of onset of embolic stroke, and 
motion of LAA. Fourth, there is a possibility that patients already developed asymptomatic AF 
before CIED implantation because asymptomatic AF is undiagnosed by the conventional method. 
Many people have a CIED, and clarification of the relationship between AHREs and embolic 
stroke events in patients with CIEDs is challenging and clinically important. Therefore, a large 
multicenter, prospective study of patients with CIEDs is needed. Although I focused on patients 
with a CIED, my observations may not apply to the general population. 
 
Conclusions 
Embolic stroke events are common in Japanese patients with CIEDs. Episodes of new-onset AF 
lasting for ≥30 seconds and an enlarged left atrium are risk factors of embolic stroke in this 
population. Therefore, when physicians detect new-onset AF in patients with CIEDs, they should 
consider a comprehensive assessment of the risk and benefit of prescribing an anticoagulant. 
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